



NAFLD EASD Study Group 2nd meeting

Florence 17-18 March 2014

Day 1

Monday 17 March 2014

8.00 bus leaving the Grand Hotel Minerva Florence

9.00-10.40 Session 1 Pathophysiology and diagnosis of NAFLD Chair: Chris Day

9.00-09.20 Quentin Anstee: Genetic and epigenetic markers of NAFLD stage and progression

09.25-09.40 Hannele Yki-Järvinen: Novel approaches to diagnose and classify NASH

09.45-10.00 Marra "Cellular mediators of inflammation in fatty liver"

10.05-10.20 Chrysi Koliaki: Hepatic energy metabolism in obese, NAFLD and type 2 diabetes

10.40-11.00 Coffee break

11.00-12.30 Session 2 Pathophysiology of NAFLD: basic Chair:

11.00-11.15 Renaud Dentin: Contribution of the histone demethylase phf2 to the development and progression of NAFLD in mice and humans- when metabolism and epigenetic converge

11.20-11.35 Sophie Lotersztajn: The role of macrophages in NAFLD progression

11.40-11.55 Philippe Gual: Hepatic autophagy regulates inflammation mediated p53 signaling, ER stress and liver injury in NAFLD

12.00-12.15 Benoit Viollet: Consequence of pharmacological AMPK activation on hepatic lipid accumulation

12.30-1.30 lunch buffet

1.30-1.45 wellcome by Lilly

1.45-3.15 2 groups will go to the tour of the Lilly facility (12x2 people)

3.15-4.20 Session 3**Bile acid metabolism and NAFLD****Chair**

03.15-03.30 Catherine Postic: Role of bile acid detoxification in progression to NASH: interplay between ChREBP and nuclear receptors

03.35-03.50 Michael Trauner: Role of bile acid signaling in NASH

03.55-04.10 Ele Ferrannini: Bile acids and diabetes

4.20-4.40 Coffee break**4.40-6.25 Session 4****Other aspects of NAFLD pathogenesis****Chair**

4.40-4.55 Norbert Stefan: Dysregulated Hepatokines in NAFLD'. Here I can present new own data about expression and some functions of the hepatokines fetuin-A, selenoprotein P and betatrophin

5.00-5.15 Jussi Pihlajamäki: Ketone body metabolism in NASH

5.20-05.35 Dan Cuthertson: Liver or visceral fat: the mediator of impaired cardiac function?

5.40-5.55 J. Bernadette Moore: "Proteomic identification of a role for glyoxalase 1 in non-alcoholic fatty liver disease pathogenesis"

6.00-6.25 What can the EASD-NAFLD study group achieve together?

6.30 bus to return to the hotel**Dinner**



NAFLD EASD Study Group 2nd meeting

Florence 17-18 March 2014

Day 2

Tuesday 18 March 2014

8.00 bus leaving the Grand Hotel Minerva Florence

9.00-10.55 Session 5 effect of Diet and and drug therapy on NAFLD Chair

09.00-09.15 - svegliati baroni: Diet Gut and NAFLD

09.20-09.35 Roy Taylor: Divergence in extent of hepatic inflammation in type 2 diabetes following onset of acute calorie restriction: a human model of transient NASH

09.40-09.55 Ulf Riserus: Dynamics of metabolic and nutritional liver fat markers using repeated MRI measures in obese subjects

10.05-10.20 Lutgarda Bozzetto Qualitative dietary changes and liver fat content

10.35-10.55 Coffee break

10.55-12.15 Session 6 effect of Diet and and drug therapy on NAFLD Chair

10.55-11.10 Margot Umpleby: Differential effect of a high sugar diet on VLDL₁ and VLDL₂ TAG kinetics in men with low versus high liver fat

11.15-11.30 Eugène Jansen: The relation of sugar (fructose) intake and NAFLD

11.35-11.50 Christopher Byrne: Effects of docosahexanoic acid tissue enrichment on hepatic fat, hepatic insulin sensitivity and markers of disease severity in people with NAFLD

11.55-12.10 Ken Cusi in NASH: Novel findings and future directions

12.15-12.45 discussion

12.45-13.45 Lunch

13.45-15.15 2 groups will go to the tour of the Lilly facility (12x2 people)

15.15-16.00 Discussion